Is Medicamen Organ. overvalued or undervalued?
As of November 4, 2025, Medicamen Organ. is considered overvalued with a PE ratio of 11.91 and an EV to EBITDA of 8.62, significantly underperforming the Sensex with a year-to-date return of -38.22%.
As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 11.91, an EV to EBITDA of 8.62, and a ROCE of 12.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.41, while Cipla, which is rated attractive, has a PE ratio of 22.35.The valuation metrics suggest that Medicamen Organ. is trading at a premium relative to its financial performance, especially when compared to peers like Dr. Reddy's Labs, which has a PE ratio of 17.36 and is rated attractive. Additionally, the company's stock has underperformed the Sensex significantly, with a year-to-date return of -38.22% compared to the Sensex's gain of 8.26%. This further reinforces the conclusion that Medicamen Organ. is currently overvalued in the market.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
